NCT05947552

Brief Summary

Variability of serum ferritin in CKD patients and how these variables may affect the treatment decisions with iron supplements

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
55

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 23, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

July 8, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 17, 2023

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 11, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 11, 2025

Completed
Last Updated

July 17, 2023

Status Verified

July 1, 2023

Enrollment Period

1.5 years

First QC Date

May 23, 2023

Last Update Submit

July 9, 2023

Conditions

Chronic Kidney Diseases

Outcome Measures

Primary Outcomes (1)

  • to assess the role of serum ferritin in CKD patients din in CKD patients and how these variability

    affect treatment decisions with iron

    Recurring

Study Arms (1)

Chronic kidney disease Patients

Chronic kidney Disease Patients stage 3 to stage 5

Drug: Serum ferritin

Interventions

Serum ferritinDRUG

Serum ferritin in CKD patients

Chronic kidney disease Patients

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

ALL CKD patients who are not dialysis Stage 3 to 5

You may qualify if:

  • ALL CKD patients stage 3 to 5 not on dialysis

You may not qualify if:

  • inflammatory chronic diseases IDA Autoimmune disorders Liver diseases Malignancy Infections

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut university

Asyut, Egypt

RECRUITING

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Hawaid Ab Nafady, Professor

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Reham Ma Osman, doctor

CONTACT

01065934817rehamaskary1234@gmail.com

Alshaimaa Sy Hassan, Professor

CONTACT

01096883911alshaimaamabarak@gmail.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assiut Lecturer

Study Record Dates

First Submitted

May 23, 2023

First Posted

July 17, 2023

Study Start

July 8, 2023

Primary Completion

January 11, 2025

Study Completion

January 11, 2025

Last Updated

July 17, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will not share

Locations

EG(1)